Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Sarah J Schlesinger"'
Autor:
Sandhya Vasan, Arlene Hurley, Sarah J Schlesinger, Drew Hannaman, David F Gardiner, Daniel P Dugin, Mar Boente-Carrera, Roselle Vittorino, Marina Caskey, Johanne Andersen, Yaoxing Huang, Josephine H Cox, Tony Tarragona-Fiol, Dilbinder K Gill, Hannah Cheeseman, Lorna Clark, Len Dally, Carol Smith, Claudia Schmidt, Harriet H Park, Jakub T Kopycinski, Jill Gilmour, Patricia Fast, Robert Bernard, David D Ho
Publikováno v:
PLoS ONE, Vol 6, Iss 5, p e19252 (2011)
DNA-based vaccines have been safe but weakly immunogenic in humans to date.We sought to determine the safety, tolerability, and immunogenicity of ADVAX, a multigenic HIV-1 DNA vaccine candidate, injected intramuscularly by in vivo electroporation (EP
Externí odkaz:
https://doaj.org/article/54e6c0214ce848db98e3291e78e074a0
Autor:
Sandhya Vasan, Sarah J Schlesinger, Yaoxing Huang, Arlene Hurley, Angela Lombardo, Zhiwei Chen, Soe Than, Phumla Adesanya, Catherine Bunce, Mark Boaz, Rosanne Boyle, Eddy Sayeed, Lorna Clark, Daniel Dugin, Claudia Schmidt, Yang Song, Laura Seamons, Len Dally, Martin Ho, Carol Smith, Martin Markowitz, Josephine Cox, Dilbinder K Gill, Jill Gilmour, Michael C Keefer, Patricia Fast, David D Ho
Publikováno v:
PLoS ONE, Vol 5, Iss 1, p e8617 (2010)
We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high
Externí odkaz:
https://doaj.org/article/ba21b6228383420b93b1fcfdfb199a37
Autor:
Sandhya Vasan, Sarah J Schlesinger, Zhiwei Chen, Arlene Hurley, Angela Lombardo, Soe Than, Phumla Adesanya, Catherine Bunce, Mark Boaz, Rosanne Boyle, Eddy Sayeed, Lorna Clark, Daniel Dugin, Mar Boente-Carrera, Claudia Schmidt, Qing Fang, LeiBa, Yaoxing Huang, Gerasimos J Zaharatos, David F Gardiner, Marina Caskey, Laura Seamons, Martin Ho, Len Dally, Carol Smith, Josephine Cox, Dilbinder Gill, Jill Gilmour, Michael C Keefer, Patricia Fast, David D Ho
Publikováno v:
PLoS ONE, Vol 5, Iss 1, p e8816 (2010)
We conducted a Phase I dose-escalation trial of ADMVA, a Clade-B'/C-based HIV-1 candidate vaccine expressing env, gag, pol, nef, and tat in a modified vaccinia Ankara viral vector. Sequences were derived from a prevalent circulating HIV-1 recombinant
Externí odkaz:
https://doaj.org/article/25b6bfc4047d47d09e9a293a9d14fcdd
Autor:
Sarah J. Schlesinger, Michelle Romanick, Jonathan N. Tobin, Donna Brassil, Rhonda G. Kost, Rita Devine, Barbara O’Sullivan, Roger D. Vaughan, Yupu Liang, Joel Correa da Rosa, Maija Williams, James G. Krueger, Barry S. Coller
Publikováno v:
Journal of Clinical and Translational Science, Vol 1, Pp 285-291 (2017)
Introduction and Methods The Rockefeller Clinical Scholars (KL2) program began in 1976 and transitioned into a 3-year Master’s degree program in 2006 when Rockefeller joined the National Institute of Health Clinical and Translational Science Award
Externí odkaz:
https://doaj.org/article/677a2c7991f24b4ca0836dd7348348af
Autor:
Tesheia Johnson, Andrea Ronning, Sarah J. Schlesinger, Michelle Romanick, Eugene D. Shapiro, Prasanth Manukonda, Barry S. Coller, Rhonda G. Kost, Riva Gottesman, Roger D. Vaughan, Maija Neville-Williams, Jonathan N. Tobin, Bernadette Capili, James G. Krueger, Rita Devine, Barbara O'Sullivan, Emma A. Meagher, Donna Brassil, Robert MacArthur
Publikováno v:
Journal of Clinical and Translational Science
The ability to effectively lead an interdisciplinary translational team is a crucial component of team science success. Most KL2 Clinical Scholars have been members of scientific teams, but few have been team science leaders. There is a dearth of lit
Autor:
Sarah J. Schlesinger, Barry S. Coller, Donna Brassil, Roger D. Vaughan, Rhonda G. Kost, Michelle Romanick
Publikováno v:
Journal of Clinical and Translational Science. 4:116-117
OBJECTIVES/GOALS: There is universal recognition of the importance of team science and team leadership. We have developed a semi-quantitative translational science specific team leadership competency assessment tool and have begun implementation stud
Autor:
Florian Krammer, Peter Palese, Sarah J. Schlesinger, Gene S. Tan, Jeffrey V. Ravetch, Taia T. Wang, Rafi Ahmed, Carl W. Davis, Jad Maamary, Stylianos Bournazos
Publikováno v:
Cell. 162(1):160-169
SummaryProtective vaccines elicit high-affinity, neutralizing antibodies by selection of somatically hypermutated B cell antigen receptors (BCR) on immune complexes (ICs). This implicates Fc-Fc receptor (FcR) interactions in affinity maturation, whic
Autor:
Clara Lehmann, Anthony P. West, Joshua A. Horwitz, Sarah J. Schlesinger, Julio C. C. Lorenzi, Maggi Witmer-Pack, Leah A. Burke, Bruce D. Walker, Gerd Fätkenheuer, Michael S. Seaman, Robert J. Gorelick, Marina Caskey, Roy M. Gulick, Gisela Kremer, Tibor Keler, Martin Platten, Lilian Nogueira, Sivan Ben-Avraham, Malte Braunschweig, Thomas Hawthorne, Michel C. Nussenzweig, Johannes F. Scheid, Florian Klein, Irina Shimeliovich, Noreen Buckley
Publikováno v:
Nature. 522:487-491
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was therefore abandoned1–3. However, recently developed single cell based antibody cloning methods ha
Autor:
Cecilia Unson-O’Brien, Daniela Weiland, Irina Shimeliovich, Michel C. Nussenzweig, Allison Settler, Edward F. Kreider, Maggi Witmer-Pack, Florian Klein, Kemal Eren, Christoph Wyen, Tim Kümmerle, Roy M. Gulick, Tibor Keler, Gerald H. Learn, Clara Lehmann, Thiago Y. Oliveira, Pamela J. Bjorkman, Caroline Ignacio, Hugo Mouquet, Yehuda Z. Cohen, Nico Pfeifer, Sarah J. Schlesinger, Michael S. Seaman, Till Schoofs, Gerd Fätkenheuer, Ben Murrell, Theodora K. Karagounis, Henning Gruell, Lilian Nogueira, Anthony P. West, Barry S. Zingman, Daniel Gillor, Marina Caskey, Beatrice H. Hahn, Rebeka Levin, Alexander. Robles, Szilard Kiss
Publikováno v:
Nature Medicine
Nat Med
Nat Med
Florian Klein and colleagues report that treating viremic HIV-1-infected individuals with the broadly neutralizing antibody 10-1074 reduced virus levels in blood, but antibody-resistant virus did emerge. Monoclonal antibody 10-1074 targets the V3 gly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5988e13709ffe50c6a1ee170b8fd18cd
https://resolver.caltech.edu/CaltechAUTHORS:20161212-163351707
https://resolver.caltech.edu/CaltechAUTHORS:20161212-163351707
Autor:
Florian Klein, Michel C. Nussenzweig, Nico Pfeifer, Yehuda Z. Cohen, Anthony P. West, Irina Shimeliovich, Marina Caskey, Tibor Keler, Gerald H. Learn, Allison Settler, Lilian Nogueira, Barry S. Zingman, Yotam Bar-On, Pamela J. Bjorkman, Sonya Hadrigan, Ching-Lan Lu, Thiago Y. Oliveira, Thomas Hawthorne, Anna Feldmann, Johannes F. Scheid, Joshua A. Horwitz, Malte Braunschweig, Boris Juelg, Bruce D. Walker, Maggi Witmer-Pack, Edward F. Kreider, Roshni Patel, Julio C. C. Lorenzi, Beatrice H. Hahn, Sarah J. Schlesinger, Michael S. Seaman, Leah A. Burke, Roy M. Gulick
Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open label clinical trial evaluating 3BNC117,a broad and potent neutralizing antibody against the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b36b4147b17c0d19add180df3161543
https://resolver.caltech.edu/CaltechAUTHORS:20160706-085949583
https://resolver.caltech.edu/CaltechAUTHORS:20160706-085949583